Loading clinical trials...

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

A Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety of Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by Insulin Dose Optimization in Subjects With Type 1 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Intensive Insulin Therapy

NCT00042458•AstraZeneca

View on ClinicalTrials.gov

Summary

This is a randomized, triple-blind, placebo-controlled, multicenter study to investigate the safety of pramlintide treatment using pramlintide dose-titration coupled with insulin adjustments in subjects with type 1 diabetes who are actively trying to improve their glycemic control.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•HbA1c value between 7.5-9%
•Using multiple daily insulin injections

Locations (33)

Ana Ventures LLC

Mesa, Arizona, United States

Phoenix Endocrinology Clinic, Ltd.

Phoenix, Arizona, United States

East Bay Clinical Trial Center

Concord, California, United States

Valley Research

Fresno, California, United States

UCSD Diabetes Research Center

San Diego, California, United States

Diabetes Research Institute

San Mateo, California, United States

Sansum Medical Research Institute

Santa Barbara, California, United States

Diablo Clinical Research

Walnut Creek, California, United States

Barbara Davis Center for Childhood Diabetes

Denver, Colorado, United States

MedStar Clinical Research Center

Washington D.C., District of Columbia, United States

Key Dates

Start Date

April 1, 2002

Primary Completion Date

March 1, 2003

Completion Date

March 1, 2003

Last Updated

September 23, 2015

Enrollment

296

ACTUAL participants

Conditions

Diabetes Mellitus, Type 1

Interventions

Pramlintide acetate

DRUG

Placebo

DRUG

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

NCT04786262

Diabetes Mellitus, Type 1Impaired Hypoglycemic Awareness+1 more

View study

RECRUITINGNA

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

NCT06748963

Diabetes Mellitus, Type 1

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 23, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

Inclusion Criteria

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

Closed Loop and Education for Hypoglycemia Awareness Restoration

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

Achieving Health in Emerging Adults With Diabetes (AHEAD) Program: A Clinical Trial Designed to Understand if Participation in a Clinical Program Developed Specifically to Support Emerging Adults With Type 1 Diabetes Leads to Improved Diabetes Outcomes.

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes